纵向尿液代谢生物标志物与ADPKD严重程度及TAME-PKD临床试验中二甲双胍反应的相关性
TAME-PKD试验为期2年,评估二甲双胍在轻中度成人ADPKD患者中的安全性和耐受性,eGFR下降趋势不显著。本研究在TAME-PKD参与者中检测尿液总蛋白、乳酸、丙酮酸、琥珀酸及糖酵解酶,横断面和纵向分析其与htTKV、eGFR及二甲双胍治疗的相关性。
要点
- 安慰剂组横断面分析中,尿肌酐标化的琥珀酸与ln(htTKV)负相关,尿蛋白与ln(htTKV)强正相关、与eGFR负相关。
- 尿乳酸/丙酮酸比值及渗透压标化的尿蛋白与eGFR存在显著时间依赖性负相关,提示与疾病进展相关。
- 渗透压标化的尿丙酮酸在二甲双胍组保持而安慰剂组下降,两组间差异显著,可能区分二甲双胍治疗效果。
核心结论
- 在TAME-PKD研究人群中,蛋白尿伴随糖酵解增强和氧化代谢标志物降低,总体与疾病严重程度和进展风险相关。
研究设计与样本
- TAME-PKD试验为期2年,在轻中度成人ADPKD患者中测试二甲双胍治疗,发现二甲双胍安全可耐受,与安慰剂相比eGFR下降趋势不显著。
- 本研究在TAME-PKD参与者中检测尿液总蛋白、靶向代谢物(乳酸、丙酮酸、琥珀酸)和糖酵解酶(丙酮酸激酶-M2、乳酸脱氢酶-A、丙酮酸脱氢酶激酶-1),并用肌酐或渗透压标化,在不同研究时间点与身高调整总肾脏体积(htTKV)和eGFR比较。
主要发现
- 利用安慰剂组数据的横断面分析中,尿肌酐标化的琥珀酸与ln(htTKV)负相关,而蛋白排泄与ln(htTKV)强正相关、与eGFR负相关。
- 尿乳酸/丙酮酸比值和渗透压标化的尿蛋白与eGFR存在显著时间依赖性负相关,表明这些生物标志物与疾病进展相关。
- 二次分析中,渗透压标化的尿丙酮酸在二甲双胍治疗参与者中保持,而在安慰剂组2年研究期间下降,两组间差异显著,提示时间依赖性尿丙酮酸变化可能作为该研究人群中二甲双胍治疗效果的区分指标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Dysregulated cellular metabolism contributes to autosomal dominant polycystic kidney disease (ADPKD) pathogenesis. The Trial of Administration of Metformin in Polycystic Kidney Disease (TAME-PKD) tested the effects of metformin treatment over 2 years in adult ADPKD patients with mild-moderate disease severity. Metformin was found to be safe and tolerable with an insignificant trend toward reduced estimated glomerular filtration rate (eGFR) decline compared to placebo. Here we tested whether targeted urinary metabolic biomarkers measured in TAME-PKD participants correlated with disease progression, severity, and metformin treatment in cross-sectional and longitudinal analyses. METHODS: Concentrations of total protein, targeted metabolites (lactate, pyruvate, and succinate), and glycolytic enzymes (pyruvate kinase-M2, lactate dehydrogenase-A, and pyruvate dehydrogenase kinase-1) were measured and normalized by creatinine or osmolality in urine specimens and compared with height-adjusted total kidney volume (htTKV) and eGFR at the different study timepoints. RESULTS: In cross-sectional analyses utilizing placebo group data, urinary succinate normalized by creatinine negatively correlated with ln (htTKV), whereas protein excretion strongly positively correlated with ln (htTKV), and negatively correlated with eGFR. Significant time-varying negative associations occurred with eGFR and the lactate/pyruvate ratio and with urine protein normalized by osmolality, indicating correlations of these biomarkers with disease progression. In secondary analyses, urinary pyruvate normalized by osmolality was preserved in metformin-treated participants but declined in placebo over the 2-year study period with a significant between-arm difference, suggesting time-dependent urinary pyruvate changes may serve as a discriminator for metformin treatment effects in this study population. CONCLUSION: Proteinuria with enhanced glycolytic and reduced oxidative metabolic markers generally correlated with disease severity and risk of progression in the TAME-PKD study population.
引用
- Hallows KR, Abebe KZ, Li H, et al. Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial Participants. Kidney Int Rep. 2022. PMID: 36938071. doi:10.1016/j.ekir.2022.11.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。